These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 25874805)
1. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. Tirani M; Meregaglia M; Melegaro A PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805 [TBL] [Abstract][Full Text] [Related]
2. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. Watson PS; Turner DP Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570 [TBL] [Abstract][Full Text] [Related]
3. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
4. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504 [TBL] [Abstract][Full Text] [Related]
5. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany. Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566 [TBL] [Abstract][Full Text] [Related]
6. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis. Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398 [TBL] [Abstract][Full Text] [Related]
7. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Moura Silveira M; McBride AJA; Trotter CL Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182 [TBL] [Abstract][Full Text] [Related]
8. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health. Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816 [TBL] [Abstract][Full Text] [Related]
10. UK parents' attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis. Jackson C; Yarwood J; Saliba V; Bedford H BMJ Open; 2017 May; 7(4):e012851. PubMed ID: 28473508 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB; Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432 [TBL] [Abstract][Full Text] [Related]
14. Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives. Signorelli C; Chiesa V; Odone A J Prev Med Hyg; 2015 Aug; 56(3):E125-32. PubMed ID: 26788733 [TBL] [Abstract][Full Text] [Related]
15. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884 [TBL] [Abstract][Full Text] [Related]
16. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641 [TBL] [Abstract][Full Text] [Related]
17. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Azzari C; Canessa C; Lippi F; Moriondo M; Indolfi G; Nieddu F; Martini M; de Martino M; Castiglia P; Baldo V; Resti M; Vaccine; 2014 Feb; 32(10):1187-91. PubMed ID: 24120548 [TBL] [Abstract][Full Text] [Related]
18. Can we control all-cause meningococcal disease in Europe? Sadarangani M; Pollard AJ Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415 [TBL] [Abstract][Full Text] [Related]
19. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement. Hogea C; Van Effelterre T; Vyse A Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796 [TBL] [Abstract][Full Text] [Related]
20. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]